Table 3.

Fosfomycin (FOS) treatment for acute and chronic bacterial prostatitis caused by antimicrobial-resistant E. coli.

Reference	Subject number	Type of bacterial prostatitisa	Age	Susceptibility		FOS MIC	MDRd mechanism	FT e dosage regimen	FT treatment duration	Microbiological eradication	Clinical cure
				CIPb	TMP-SMXc
[7]	1	C	80	Rg	R	—	AmpC	3 g·q 72 h	6 weeks	Yes	Yes
	2	C	52	R	R	—	ESBLi	3 g·q 72 h	6 weeks	Yes	Yes
	3	C	54	R	S	—	ESBL	3 g·q 72 h	6 weeks	No	No
	4	C	54	R	R	—	—	3 g·q 72 h	6 weeks	No	No
	5	C	31	R	S	—	—	3 g·q 72 h	6 weeks	No	No
	6	C	29	Sh	S	—	ESBL	3 g·q 72 h	6 weeks	Yes	Yes
	7	C	57	R	R	—	—	3 g·q 72 h	6 weeks	Yes	Yes
	8	C	22	R	R	—	—	3 g·q 72 h	6 weeks	Yes	Yes
	9	C	44	S	R	—	—	3 g·q 72 h	6 weeks	No	No
	10	C	59	R	S	—	ESBL	3 g·q 72 h	6 weeks	Yes	Yes
	11	C	49	R	R	—	—	3 g·q 72 h	6 weeks	Yes	No
	12	C	70	R	S	—	—	3 g·q 72 h	6 weeks	No	No
	13	C	65	S	S	—	—	3 g·q 48 h	6 weeks	No	No
	14	C	54	S	S	—	—	3 g·q 48 h	6 weeks	Yes	Yes
[24]	1	A/C	73	R	—	1 μg/mL	ESBL	3 g OD/BID	16 weeks	Yes	Yes
	2	A	80	R	—	1 μg/mL	ESBL	3 g OD	12 weeks	Yes	Yes
[22]	1	C	53	R	—	2 μg/mL	ESBL	3 g·q 72 h∗	2 weeks	Yes	Yes
[25]	13 total	C	53.6f	8/13 R	7/13 R	13/13 S	2/13 ESBL	3 g OD q 48 h	7 weeks	—	∼77%

^aA, acute prostatitis; C, chronic prostatitis; U, unspecified; ^bCIP, ciprofloxacin; ^cTMP-SMX, trimethoprim-sulfamethoxazole; ^dMDR, multidrug-resistant; ^eFT, fosfomycin tromethamine; ^fmean age (years); ^gR, resistant; ^hS, susceptible; ⁱESBL, extended-spectrum β-lactamase; ^jMBL, metallo-β-lactamase; ^∗combination therapy of oral FT (3 g q 72 h) and oral doxycycline (100 mg q 12 h).